Erratum to “Intensive care management of influenza-associated pulmonary aspergillosis” (Clinical Microbiology and Infection (2019) 25(12) (1501–1509), (S1198743X19302095), (10.1016/j.cmi.2019.04.031))

The publisher regrets that during the copyediting process quaque die (QD), once a day was miss-edited to quater in die (QID), four times a day in the second paragraph of the Management bundle section. The originally submitted, correct statements are given below. […] When invasive aspergillosis is diagnosed, isavuconazole (loading dose 200mg three times a day, intravenously for two days (six administrations), from day 3 200mg once a day, intravenously (12 to 24 hours after last loading dose administered)) or voriconazole (loading dose 6mg/kg BW twice a day, intravenously on day one, from day two 4mg/kg BW twice a day, intravenously), currently represent the first-line recommended options.42 […] […] Liposomal amphotericin B (3mg/kg BW once a day, intravenously), posaconazole (loading dose 300mg twice a day, intravenously on day one, from day two 300mg once a day, intravenously) and echinocandins are considered second-line options in refractory cases or when voriconazole or isavuconazole are contraindicated.42 […] […] In case of disease progression after therapy initiation (refractory disease) a switch to another drug class e.g. to liposomal amphotericin B (3mg/kg once a day, intravenously) or an echinocandin is recommended.42 […] The publisher would like to apologise for any inconvenience caused.